|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Clinical experience and acceptability of the etonogestrel subdermal |
| contraceptive implant. [Experiencia clínica y aceptabilidad del implante |
| anticonceptivo subdérmico de etonogestrel.] |
| Flores JB; Balderas ML; Bonilla MC; Vázquez-Estrada L |
| International Journal of Gynecology and Obstetrics. 2005 Sep;90(3):228-233. |
| The objective was to evaluate efficacy, adverse effects, and user continuation rate of an etonogestrel subdermal |
| single-rod contraceptive implant. A total of 417 healthy volunteers of childbearing age were included in this |
| multicenter trial. After implant insertion, the women were followed up during the 3 years of contraceptive action. At |
| each visit, clinical findings, side effects, and bleeding patterns were recorded. Efficacy and continuation rates were |
| analyzed using the Pearl Index and Kaplan-Meier life tables, respectively. The observation period totaled 958.5 |
| woman-years (27.5 months per woman). The Pearl Index score was 0. Side effects were reported by 44.4% of users, |
| but the proportion had decreased to 16.5% by the end of the study. The continuation rate was 61.4%. The most |
| common reason for early discontinuation (in 21.1% of the participants) was menstrual disturbances. Etonogestrel |
| subdermal contraceptive implants demonstrated high efficacy and an acceptable continuation rate. Counseling |
| potential users explicitly about the side effects will optimize patient success with this long-acting contraceptive. |
| (PubHealth.info Document ID: CONT1T 79-06) |
| PubHealth.info NOTE: The author(s) of this article titled, "Clinical experience and acceptability of the etonogestrel |
| subdermal contraceptive implant. [Experiencia clínica y aceptabilidad del implante anticonceptivo subdérmico de |
| etonogestrel.]", is(are) Flores JB; Balderas ML; Bonilla MC; Vázquez-Estrada L. The source of this article is |
| "International Journal of Gynecology and Obstetrics. 2005 Sep;90(3):228-233.". This article was published in 2005 in |
| English language(s). (PubHealth.info® Document ID: CONT1T 79-06. All rights reserved with PubHealth.info) PIN: 79 |
| This article is peer-reviewed. |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |
